uTPI: a utility-based toxicity probability interval design for phase I/II dose-finding trials
From MaRDI portal
Publication:6627822
DOI10.1002/SIM.8922zbMATH Open1546.62681MaRDI QIDQ6627822
Ruitao Lin, Ying Yuan, Haolun Shi, Jiguo Cao
Publication date: 29 October 2024
Published in: Statistics in Medicine (Search for Journal in Brave)
utilitydose findingphase I/II trialsoptimal biological doseBayesian quasi likelihooddose desirability
Cites Work
- Title not available (Why is that?)
- Dose-Finding Based on Efficacy-Toxicity Trade-Offs
- Cumulative cohort design for dose-finding
- Bayesian Dose-Finding in Phase I/II Clinical Trials Using Toxicity and Efficacy Odds Ratios
- Utility-Based Optimization of Combination Therapy Using Ordinal Toxicity and Efficacy in Phase I/II Trials
- Pseudo Maximum Likelihood Methods: Theory
- Bayesian Dose-Finding in Two Treatment Cycles Based on the Joint Utility of Efficacy and Toxicity
- The Continual Reassessment Method for Multiple Toxicity Grades: A Bayesian Quasi‐Likelihood Approach
- A utility-based Bayesian optimal interval (U-BOIN) phase I/II design to identify the optimal biological dose for targeted and immune therapies
- An information theoretic phase I--II design for molecularly targeted agents that does not require an assumption of monotonicity
Related Items (2)
Comparative review of novel model-assisted designs for phase I/II clinical trials ⋮ BIPSE: a biomarker-based phase I/II design for immunotherapy trials with progression-free survival endpoint
This page was built for publication: uTPI: a utility-based toxicity probability interval design for phase I/II dose-finding trials
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q6627822)
